DSI Validation Study
Research type
Research Study
Full title
Validation of a disease severity index for Crohn's disease and ulcerative colitis
IRAS ID
247684
Contact name
Patrick Allen
Contact email
Sponsor organisation
University of Otago
Duration of Study in the UK
0 years, 9 months, 31 days
Research summary
The inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC), are chronic and often disabling conditions. Although most treatment in IBD begin with classifying patients according to disease severity, there are no agreed definitions of mild, moderate, or severe IBD currently in existence. Basing overall disease severity on symptoms alone does not account for the wide variety of patient symptoms that drive decisions towards appropriate therapy, including bowel damage and impact on daily activities (disability).
In an effort to move from categorising patients based on current disease activity towards a more global disease severity, Peyrin-Biroulet et al. has recently published a systematic review identifying three main elements for the evaluation of disease severity in IBD: impact of the disease on the patient regarding symptoms and daily activities, inflammatory burden, and disease course.
A recent work (under review, Corey A. Siegel et al., looking beyond symptoms and disease activity to define overall disease severity in inflammatory bowel disease: results of an International Organization For the Study of Inflammatory Bowel Disease I(OIBD) specialist panel) have identified the key attributes that contribute to overall IBD severity and defined two Overall Disease Severity Indices (DSI) for patients with Crohn’s disease (CD) and ulcerative colitis (UC).REC name
South Central - Oxford A Research Ethics Committee
REC reference
19/SC/0225
Date of REC Opinion
6 May 2019
REC opinion
Unfavourable Opinion